Uncertainty over the expansion of regenerative-inducing medicine indications and market size
First written in FY2020. 3 of 4 entries say "Restated". Latest entry: FY2025.
2 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「However, if the scope of indications cannot be expanded as anticipated by the Company for any reason, this may have a significant impact on future operating results.」
The risk that expansion of indications for regenerative medicine products and market acquisition will not progress as anticipated has been reconfirmed. - FY2024RestatedAnnual report
「However, if the scope of indications cannot be expanded as anticipated by the Company for any reason, this may have a significant impact on future operating results.」
The risk that expansion of indications for regenerative medicine products and market acquisition will not progress as anticipated has been reconfirmed. - FY2022RestatedAnnual report
「However, if the scope of indications cannot be expanded as anticipated by the Company for any reason, this may have a significant impact on future operating results.」
The risk that expansion of indications for regenerative medicine products and market acquisition will not progress as anticipated has been reconfirmed. - FY2020First statedAnnual report
「However, if the scope of indications cannot be expanded as anticipated by the Company for any reason, this may have a significant impact on future operating results.」
While anticipating expansion into a broad range of diseases and the acquisition of a substantial market, the Company describes the impact on operating results if the scope of indications cannot be expanded as a risk.